

Appendix 2. Baseline characteristics of the studied Saudi cohort of DISCOVER study.

Variables	Baseline data for 519 patients
Mean age (years) (SD)	52.4 (\pm 11.0)
Gender n(%)	
Males	284 (54.7)
Females	235 (45.3)
Any Macrovascular Disease n (%)	57 (11)
Coronary artery disease n (%)	38 (7.3)
Myocardial infarction n (%)	8 (1.5)
Angina n (%)	12 (2.3%)
Atrial fibrillation event	4 (0.8)
Heart failure n (%)	8 (1.5)
Peripheral vascular disease n (%)	0 (0)
Stroke n (%)	12 (2.3)
TIA n (%)	6(1.2)
Chronic Kidney Disease n (%)	7 (4)
Albuminuria	16 (3.1)
Retinopathy n (%)	22 (4.3)
Peripheral neuropathy n (%)	59 (11)
Autonomic neuropathy n(%)	35 (6.8)
Hypertension n (%)	196 (37.8)
Hyperlipidemia n (%)	226 (43.5)
First-line hypoglycemic medications n (%)	
Biguanides	463 (89.2)
Sulfonylurea	246 (47.5)
DPP-4 inhibitors	48 (9.3)
Thiazolidinedione/ glitazones	2 (0.4)
Second-line hypoglycemic medications n (%)	
Biguanides	475 (91.5)
Sulfonylurea	232 (51.2)
DPP-4 inhibitors	384 (73.9)
Thiazolidinedione/ glitazones	24 (4.6)
Alph-glucosidase inhibitors	5 (1)
Meglitinides/Glinides	3 (0.6)
Incretin mimetics/GLP1	4 (0.8)
Insulin	46 (8.9)

